The PE-conjugated Rat Monoclonal anti-TACI antibody (Clone 1A1) (ABIN2663249) specifically detects TACI in FACS and ICFC.
The antibody is reactive with Human samples.
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Protect from prolonged exposure to light. Do not freeze.
Storage
4 °C
Storage Comment
The antibody solution should be stored undiluted between 2°C and 8°C.
Target
TACI (TNFRSF13B)
(Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))
Alternative Name
CD267
Background
TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.